Lanoxin®
Digoxin is a cardiac glycoside used for heart failure and atrial fibrillation rate control. One of the oldest cardiovascular drugs still in clinical use.
| Dosage Form | Oral Tablet / IV Injectable |
| Strength | 0.0625 mg, 0.125 mg, 0.25 mg (oral); 0.25 mg/mL (IV) |
| Storage | Store at 25°C. Protect from light. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
Heart failure (symptomatic, in addition to ACE inhibitors/beta-blockers/diuretics); atrial fibrillation (rate control).
Inhibits Na+/K+-ATPase pump, increasing intracellular calcium and enhancing cardiac contractility (positive inotrope). Also increases vagal tone, slowing AV conduction.
Each Burrard Pharmaceuticals technology transfer package for Digoxin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.